Skip to main content
Clinical Trials/NL-OMON28697
NL-OMON28697
Completed
N/A

A FIXED-SEQUENCE CROSSOVER, DRUG-DRUG INTERACTION STUDY IN HEALTHY SUBJECTS

Denali Therapeutics, Inc0 sites16 target enrollmentTBD

Overview

Phase
N/A
Intervention
Not specified
Conditions
Not specified
Sponsor
Denali Therapeutics, Inc
Enrollment
16
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

o

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • Subjects enrolled in the study were required to meet all the following criteria for study entry:
  • Men or women of any race, between 18 and 50 years of age, inclusive, at screening
  • BMI between 18\.0 and 31\.0 kg/m2, inclusive, and a body weight of at least 50\.0 kg at Screening
  • In good health determined by no clinically significant findings from medical history, physical examination, and vital sign measurements
  • All clinical laboratory tests must be within normal limits or no clinically significant abnormalities

Exclusion Criteria

  • Subjects who met any of the following criteria were excluded from study entry:
  • History of clinically significant hematological, renal, pancreatic, gastrointestinal, hepatic, cardiovascular, metabolic, endocrine, immunological, allergic disease, or other major disorders as determined by the investigator
  • Abnormal vital signs at screening
  • Clinically significant neurologic disorder
  • Evidence of ANY hepatic impairment
  • Clinically significant ECG abnormality at screening
  • History of clinically significant congestive heart failure.

Outcomes

Primary Outcomes

Not specified

Similar Trials